Kangho Suh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6179399/publications.pdf

Version: 2024-02-01

		1162367	887659
19	336	8	17
papers	citations	h-index	g-index
19	19	19	626
all docs	docs citations	times ranked	citing authors
an docs	does citations	tilles fallked	citing authors

#	Article	IF	CITATIONS
1	Economic Burden of COPD in the Presence of Comorbidities. Chest, 2015, 148, 138-150.	0.4	169
2	Assessing the importance of predictors in unplanned hospital readmissions for chronic obstructive pulmonary disease. ClinicoEconomics and Outcomes Research, 2015, 7, 37.	0.7	34
3	Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer. Pharmacoeconomics, 2018, 36, 495-504.	1.7	24
4	Consensus Obtained for the Nephrotoxic Potential of 167 Drugs in Adult Critically Ill Patients Using a Modified Delphi Method. Drug Safety, 2022, 45, 389-398.	1.4	20
5	Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel®. Advances in Therapy, 2016, 33, 1279-1292.	1.3	19
6	Analysis of Glycemic Control of a Pharmacist-Led Medication Management Program in Patients with Type 2 Diabetes. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 32-37.	0.5	17
7	Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment. Research in Social and Administrative Pharmacy, 2020, 16, 1033-1040.	1.5	13
8	Effectiveness of Gastric Bypass Versus Gastric Sleeve for Cardiovascular Disease: Protocol and Baseline Results for a Comparative Effectiveness Study. JMIR Research Protocols, 2020, 9, e14936.	0.5	8
9	Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs. Journal of Managed Care & Decialty Pharmacy, 2017, 23, 1084-1090.	0.5	7
10	Defining and Managing High-Priced Cures: Healthcare Payers' Opinions. Value in Health, 2019, 22, 648-655.	0.1	7
11	Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa. Journal of Medical Economics, 2021, 24, 563-569.	1.0	5
12	A systematic review of cost-effectiveness analyses across the acute kidney injury landscape. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 571-578.	0.7	3
13	Latent Class Analysis of Prescribing Behavior of Primary Care Physicians in the Veterans Health Administration. Journal of General Internal Medicine, 2022, , 1.	1.3	3
14	Health economics and outcomes research fellowship practices reviewed. Research in Social and Administrative Pharmacy, 2015, 11, 280-287.	1.5	2
15	Trends in healthcare expenditures and resource utilization among a nationally representative population with opioids in the United States: a serial cross-sectional study, 2008 to 2017. Substance Abuse Treatment, Prevention, and Policy, 2021, 16, 80.	1.0	2
16	Exploring Medication Adherence with P2Y12 Inhibitors Using Conditional and Unconditional Quantile Regression Approaches. American Journal of Cardiovascular Drugs, 2021, 21, 193-204.	1.0	1
17	Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients. BioDrugs, 2021, 35, 61-73.	2.2	1
18	International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility. International Journal of Environmental Research and Public Health, 2021, 18, 670.	1.2	1

#	ARTICLE	IF	CITATIONS
19	The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma. Journal of Managed Care & Decialty Pharmacy, 2022, , 1-9.	0.5	O